NASD · Healthcare · Biotechnology · USA
Marker Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Marker Therapeutics is a clinical-stage immuno-oncology company developing T cell-based immunotherapies for hematological malignancies and solid tumors. Its MAR-T cell technology selectively expands natural tumor-specific T cells from patients' or donors' blood to recognize and kill cancer cells without genetic modification. The company is evaluating multiple product candidates in clinical trials for lymphoma, pancreatic cancer, and acute myeloid leukemia.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Marker Therapeutics Inc stock.
Slightly undervalued: intrinsic value $1.01 per share, market price $0.84, margin of safety 16.9% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $1.01; the price of $0.84 is 17% below that value.
17 more in this industry show a wider margin of safety.
MRKR is slightly undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $1.01; the price of $0.84 is 17% below that value.
$1.01 per share (as of the 2026-11-17 close), against a market price of $0.84. That is a margin of safety of 16.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.